ORALLY ADMINISTRABLE LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, WITH ACE INHIBITORS FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN
The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with ACE inhibitors in order to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with lisinopril in particular.
1 - 22 . (canceled)
23 . A pharmaceutical composition for treatment of vascular disease, in a mammalian patient, comprising:
reduced glutathione in a liposomal formulation capable of administration orally, dermally or mucosally, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM; and
an ACE inhibitor.
24 . The pharmaceutical composition according to claim 23 , further comprising:
selenium.
25 . A pharmaceutical composition for treatment of vascular disease, in a mammalian patient, comprising:
reduced glutathione in a liposomal formulation capable of administration orally, dermally or mucosally, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM; and
lisinopril.
26 . The pharmaceutical composition according to claim 25 , further comprising:
selenium.